Dose-finding comparative study on biapenem in the treatment of chronic respiratory tract infections

Fumio Matsumoto, Takeo Imai, Iwao Sakurai, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Shousaku Abe, Yasuto Honda, Kyuichiro Sekine, Yuji Inoue, Tomofumi Igarashi, Sumio Iwai, Hideaki Watanabe, Masashi Tamura, Kazuki Konishi, Kazuo Obara, Kunio Shirato, Yasuo Tanno, Ruriko Sato, Toshihiro NukiwaAkira Watanabe, Yoshihiro Honda, Kazunao Niizuma, Hiroyuki Kobayashi, Hiroshi Oshitani, Masahiko Yoshida, Kaoru Shimada, Takashi Inamatsu, Yoshisige Masuda, Yasuyuki Sano, Yasuo Arai, Chiaki Arai, Yasuko Tanaka, Osamu Sakai, Kohya Shiba, Masaki Yoshida, Atsushi Saito, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Shigeki Odagiri, Midori Sumitomo, Yoshihiro Hirai, Eri Hagiwara, Taizai Amano, Masaaki Arakawa, Kohichi Wada, Shigeyuki Hoshino, Hiroki Tsukata, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Fumio Miki, Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Kotaro Ohizumi, Masato Tanaka, Kohei Hare, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Masao Nakatomi, Kazuhiro Okuno, Kiyoyasu Fukushima, Kazuo Sasayama, Yuichi Inoue, Takakazu Ohtsubo, Keizo Matsumoto, Takeshi Nagatake, Yoshiaki Utsunomiya, Hironori Masaki, Mikio Tagushi, Masakazu Takasugi, Masaru Nasu, Yoichiro Goto, Tohru Yamasaki, Atsushi Saito, Hiroshi Fukuhara, Kinko Ohwan, Hisayuki Uehara, Mitsuyoshi Nakashima

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

In order to find the optimal dose Of biapenem (BIPM), a carbapenem antibiotic, for the treatment of chronic respiratory tract infections, a comparative study was performed using imipenem/cilastatin sodium (IPM/CS) as a control drug, and the following results were obtained. BIPM at 0.3 (group L) or 0.6 (group H) g/day in two-divided doses and IPM/CS at 1.0g/1.0g/day (group C) in two-divided doses were systemically administered for 14days. 1) Clinical effects: The rates for excellent efficacy and efficacy rates were 10.7%(3/28) and 82.1%(23/28), respectively, in group L, 25.0%(6/24) and 83.3%(20/24) in group H, and 17.4%(4/23) and 78.3%(18/23) in group C. There were no significant differences among the 3 groups. 2) Bacteriological effects: The bacterial eradication rates were 76.2%(16/21) in group L, 81.3%(13/16) in Group H and 93.3%(14/15) in C group. There were no significant differences among the 3 groups. 3) Side effects were observed at a rate of 3.6%(1/28) in group L, 3.8%(1/26) in group H and 8.0%(2/28) in C group. None of these side effects were serious. 4) Abnormal laboratory findings were observed at a rate of 17.9%(5/28) in group L, 19.2%.(5/26) in group H and 28.0%(7/25) in group C. These abnormal findings were not serious. 5) Usefulness: Very useful and useful rates were 10.7%(3/28) and 82.1%(23/28), respectively, in group L, 20.0%(5/25) and 80.0%(20/25) in group H, and 16.7%(4/24) and 70.8%(17/14) in group C. There were no significant differences among the 3 groups. Based on these results, we concluded that 0.6 g a day was the optimal dosage of BIPM in the treatment of chronic respiratory tract infections from the point of view of efficacy and safety.

Original languageEnglish
Pages (from-to)1269-1284
Number of pages16
JournalChemotherapy
Volume42
Issue number11
DOIs
Publication statusPublished - 1994

Keywords

  • Chronic respiratory tract infection (RTI)
  • Dose-finding study
  • biapenem
  • imipenem/cilastatin sodium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Dose-finding comparative study on biapenem in the treatment of chronic respiratory tract infections'. Together they form a unique fingerprint.

Cite this